Background of the European Nursing Guideline Committee

During a round table discussion at the 8th meeting of the International Nursing Group for Immunodeficiencies (INGID), Netherlands, 2008, a need for European guidelines was identified. A group of 10 European expert immunology nurses came together in Amsterdam to discuss aims and write the guidelines.

The first meeting took place in July 2014, with independent medical writers to record the meeting minutes and structure the document, and was financially sponsored by Baxter. In October 2015, the current document named 'European Nursing Guidelines for Immunoglobulin Administration' was finalised.

Although the guidelines are named European Nursing Guidelines, they can be used by nurses all over the world. They are written to give an overview of the use of human, normal immunoglobulins as replacement therapy or immunomodulatory therapy in both children and adults with primary and secondary immunodeficiencies, or neurology, haematology and dermatology indications. Local guidelines and regulations regarding the administration of immunoglobulins that differ from the advices given here should be followed.

The 'European Nursing Guidelines for Immunoglobulin Administration" is evidence-based as far as possible. At the last page an explanation of different levels of evidence in clinical and medical literature is given.